- Home
- LICN vs ITRM Comparison
LICN vs ITRM Comparison
Compare LICN & ITRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LICN
- ITRM
- Stock Information
- Founded
- LICN 2004
- ITRM 2015
- Country
- LICN China
- ITRM Ireland
- Employees
- LICN N/A
- ITRM N/A
- Industry
- LICN
- ITRM Biotechnology: Pharmaceutical Preparations
- Sector
- LICN
- ITRM Health Care
- Exchange
- LICN Nasdaq
- ITRM Nasdaq
- Market Cap
- LICN 2.1M
- ITRM 35.6M
- IPO Year
- LICN 2023
- ITRM 2018
- Fundamental
- Price
- LICN $3.31
- ITRM $1.02
- Analyst Decision
- LICN
- ITRM Strong Buy
- Analyst Count
- LICN 0
- ITRM 2
- Target Price
- LICN N/A
- ITRM $7.00
- AVG Volume (30 Days)
- LICN 50.3K
- ITRM 571.6K
- Earning Date
- LICN 01-01-0001
- ITRM 05-13-2025
- Dividend Yield
- LICN N/A
- ITRM N/A
- EPS Growth
- LICN N/A
- ITRM N/A
- EPS
- LICN N/A
- ITRM N/A
- Revenue
- LICN $41,477,000.00
- ITRM N/A
- Revenue This Year
- LICN N/A
- ITRM N/A
- Revenue Next Year
- LICN N/A
- ITRM $108.39
- P/E Ratio
- LICN N/A
- ITRM N/A
- Revenue Growth
- LICN 4.32
- ITRM N/A
- 52 Week Low
- LICN $0.04
- ITRM $0.81
- 52 Week High
- LICN $7.55
- ITRM $3.02
- Technical
- Relative Strength Index (RSI)
- LICN 45.62
- ITRM 42.76
- Support Level
- LICN $3.26
- ITRM $0.88
- Resistance Level
- LICN $3.96
- ITRM $1.14
- Average True Range (ATR)
- LICN 0.39
- ITRM 0.11
- MACD
- LICN -0.03
- ITRM -0.01
- Stochastic Oscillator
- LICN 3.64
- ITRM 25.93
About LICN Lichen China Limited
Lichen International Ltd formerly Lichen China Ltd is a holding company. The company, along with its subsidiaries provides financial and taxation solution services; education support services; and software and maintenance services. The company generates Majority revenue from Financial and taxation solution services.
About ITRM Iterum Therapeutics plc
Iterum Therapeutics PLC is a pharmaceutical company dedicated to maximizing the commercial potential of Orlynvah, an oral-branded penem available in the United States and potentially the first and only oral and intravenous (IV) branded penem available globally. Its product Orlynvah has the potential to be a treatment for complicated urinary tract infections caused by the designated microorganisms, without the presence of known toxicities of some other antibiotics. The company operates in a single business segment, which is the development and commercialization of treatments for drug-resistant bacterial infections.